Search

Displaying results 2121 - 2130 of 10000 in total
  1. Drug

    Festuca pratensis pollen

    go.drugbank.com/drugs/DB10370
    Approved

    Festuca pratensis pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Six Standardized Grasses
  2. Drug

    Carboprost tromethamine

    go.drugbank.com/drugs/DB00429
    ApprovedInvestigational

    A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.

  3. Drug

    Modafinil

    go.drugbank.com/drugs/DB00745
    ApprovedInvestigational

    The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.

  4. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection … Inhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin

  5. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    [L27996] In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name

  6. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.

  7. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [L43642] Eladocagene exuparvovec received EMA approval in July 2022. … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

    Categories: Complex Mixtures
  8. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].

  9. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    [L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve … By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.

    International brands: Kalymin N
  10. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.